News

Novo Nordisk Skeptic Finally Upgrades Stock After Drop From Peak

(Bloomberg) -- A long-term Novo Nordisk A/S skeptic recommended buying shares of the Danish weight-loss drug maker nine years after starting coverage of the stock.Most Read from BloombergTrump DEI Purge Hits Affordable Housing GroupsElectric Construction Equipment Promises a Quiet RevolutionNYC Congestion Pricing Toll Gains Support Among City ResidentsOpen Philanthropy Launches $120 Million Fund To Support YIMBY ReformsProspect Medical’s Pennsylvania Hospitals at Risk of ClosureKepler Cheuvreux’

Europe's top money managers start to bring defence stocks in from the cold

European asset managers are reconsidering their policies on investing in defence, under pressure from clients and some politicians to loosen restrictions and help fund the continent's race to re-arm. Under European Union rules, a number of funds badged as sustainable need to ensure their investments 'Do No Significant Harm'. Many have avoided the sector entirely, with even engine maker Rolls Royce and Airbus, which has a big commercial aviation division, judged off limits.

Wall Street powerhouse BNY takes minority stake in EquiLend

The securities lending industry enables investors to borrow and lend stocks, bonds and other assets to facilitate liquidity management and trading strategies. Major banks, asset managers and hedge funds rely on securities lending to optimize portfolio returns and meet regulatory capital requirements. EquiLend is partly owned by some of Wall Street's biggest heavyweights, including Goldman Sachs, BlackRock, JPMorgan Chase and Bank of America Merrill Lynch.

3 Stocks Under $50 in the Doghouse

Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and investors should exercise caution as some have shaky business models.

3 Small-Cap Stocks in Hot Water

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.